Ligand Pharmaceuticals Incorporated (LGND) Insider Trading
- $5,095,853.39
- $210,833,691.85
- March 5, 2024
- John L Higgins
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| May 2, 2016 | Director | 1,000 | $121.57 | Sell | $121,570.00 | |
| April 6, 2016 | Director | 5,000 | $115.00 | Sell | $575,000.00 | |
| March 17, 2016 | COO | 6,400 | $96.70 | Sell | $618,880.00 | |
| March 8, 2016 | Director | 6,129 | $101.18 | Sell | $620,132.22 | |
| March 7, 2016 | CEO | 10,833 | $102.47 | Sell | $1,110,057.51 | |
| Jan. 20, 2016 | Director | 1,666 | $94.94 | Sell | $158,170.04 | |
| Nov. 11, 2015 | Director | 7,719 | $101.00 | Sell | $779,619.00 | |
| Aug. 17, 2015 | Director | 4,000 | $95.98 | Sell | $383,920.00 | |
| Aug. 13, 2015 | Director | 49,800 | $96.26 | Sell | $4,793,748.00 | |
| July 10, 2015 | VP | 14,067 | $99.14 | Sell | $1,394,602.38 | |
| June 26, 2015 | COO | 12,500 | $100.97 | Sell | $1,262,125.00 | |
| June 22, 2015 | COO | 23,046 | $96.45 | Sell | $2,222,786.70 | |
| June 10, 2015 | CFO | 4,125 | $93.50 | Sell | $385,687.50 | |
| June 9, 2015 | CEO | 10,000 | $92.88 | Sell | $928,800.00 | |
| June 4, 2015 | Director | 1,640 | $92.68 | Sell | $151,995.20 | |
| May 20, 2015 | Director | 9,240 | $87.34 | Sell | $807,021.60 | |
| May 14, 2015 | CFO | 68,363 | $83.91 | Sell | $5,736,339.33 | |
| March 19, 2015 | Director | 4,591 | $74.42 | Sell | $341,662.22 | |
| Feb. 10, 2015 | VP | 2,300 | $56.34 | Sell | $129,582.00 | |
| Oct. 15, 2014 | Director | 2,000 | $45.68 | Buy | $91,360.00 | |
| Oct. 9, 2014 | Director | 11,000 | $42.99 | Buy | $472,890.00 | |
| Aug. 15, 2014 | CEO | 1,000 | $54.97 | Buy | $54,970.00 | |
| June 9, 2014 | Director | 1,100 | $69.68 | Sell | $76,648.00 | |
| May 27, 2014 | VP | 7,166 | $66.90 | Sell | $479,405.40 | |
| March 25, 2014 | Insider | 78,226 | $70.09 | Sell | $5,482,860.34 | |
| March 19, 2014 | Director | 7,500 | $79.57 | Sell | $596,775.00 | |
| March 18, 2014 | Director | 5,000 | $78.83 | Sell | $394,150.00 | |
| Feb. 20, 2014 | major shareholder | 422,900 | $73.81 | Sell | $31,214,249.00 | |
| Feb. 18, 2014 | Director | 41,900 | $75.71 | Sell | $3,172,249.00 | |
| Feb. 14, 2014 | COO | 22,500 | $79.54 | Sell | $1,789,650.00 | |
| Feb. 14, 2014 | Director | 40,320 | $76.44 | Sell | $3,082,060.80 | |
| Dec. 12, 2013 | COO | 6,000 | $53.40 | Sell | $320,400.00 | |
| Dec. 6, 2013 | CFO | 6,000 | $56.08 | Sell | $336,480.00 | |
| Oct. 18, 2013 | CEO | 10,000 | $55.00 | Sell | $550,000.00 | |
| Sept. 23, 2013 | major shareholder | 359,023 | $44.50 | Sell | $15,976,523.50 | |
| Sept. 12, 2013 | Director | 160,000 | $46.78 | Sell | $7,484,800.00 | |
| Aug. 30, 2013 | VP | 28,323 | $47.54 | Sell | $1,346,475.42 | |
| Aug. 16, 2013 | VP | 14,583 | $42.63 | Sell | $621,673.29 | |
| Aug. 16, 2013 | CEO | 10,000 | $42.85 | Sell | $428,500.00 | |
| Aug. 16, 2013 | CFO | 7,500 | $42.75 | Sell | $320,625.00 | |
| June 28, 2013 | COO | 1,059 | $17.36 | Buy | $18,384.24 | |
| May 10, 2013 | VP | 4,000 | $26.66 | Sell | $106,640.00 | |
| Jan. 23, 2013 | Major Shareholder | 39,600 | $19.78 | Buy | $783,288.00 | |
| Dec. 14, 2012 | Major Shareholder | 5,386 | $18.63 | Buy | $100,341.18 | |
| Dec. 6, 2012 | Major Shareholder | 50,100 | $17.94 | Buy | $898,794.00 | |
| Dec. 5, 2012 | CEO | 2,000 | $18.03 | Buy | $36,060.00 | |
| Oct. 31, 2012 | Major Shareholder | 16,591 | $15.19 | Buy | $252,017.29 | |
| Aug. 29, 2012 | Director | 2,743 | $16.36 | Buy | $44,875.48 |
Insiders are both buying and selling Ligand Pharmaceuticals Incorporated stock.
The insider traders at Ligand Pharmaceuticals Incorporated are: Matthew W Foehr, John L Higgins, Jason Aryeh, John W Kozarich, Charles S Berkman, Todd C Davis, Bvf Partners L P/Il, Stephen L Sabba, Melanie J Herman, David M Knott, Bvf Partners P/Il, John L Lamattina, David Knott, Nishan M Desilva, Sunil Patel, John Sharp, Charles Berkman, Matthew E Korenberg, Matthew Foehr, Octavio Espinoza, Todd Davis, John Higgins, John Lamattina, John W. Kozarich, Melanie J. Herman, and Andrew Reardon
The most active insider trader at Ligand Pharmaceuticals Incorporated is Matthew W Foehr with 27 trades.
Bvf Partners P/Il has sold the most Ligand Pharmaceuticals Incorporated stock with a total value of $58,156,493.18.
Bvf Partners L P/Il has bought the most Ligand Pharmaceuticals Incorporated stock with a total value of $2,817,728.47.
The most recent insider trade for Ligand Pharmaceuticals Incorporated was on March 5, 2024.
The single biggest insider buy for Ligand Pharmaceuticals Incorporated was from Bvf Partners L P/Il with a total value of $898,794.00 on Dec. 6, 2012.
The single biggest insider sell for Ligand Pharmaceuticals Incorporated was from Bvf Partners P/Il with a total value of $31,214,249.00 on Feb. 20, 2014.